CEOs and Contract Manufacturers Targeted in Latest Warning Letters

This article was originally published in The Gold Sheet

01 Dec 2010
News

Joanne S. Eglovitch joanne.eglovitch@informa.com

Executive Summary

FDA sent six of its last nine drug GMP warning letters to contract manufacturing facilities. Most of the letters emphasized corporate accountability, and many went directly to CEOs.

Already Registered? Sign in to continue reading.

New to Pink Sheet? Start a free trial today!

Table
View full table

ASK THE ANALYST
Email

Print
Bookmark
Share

Tags:

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

PS000566

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

PS000566

All set! This article has been sent to my@email.address.

All fields are required. For multiple recipients, separate email addresses with a semicolon.

Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.

CEOs and Contract Manufacturers Targeted in Latest Warning Letters

News

Executive Summary

Related Content

FDA Drug GMP Warning Letters Increase 6%, Focus on Supply Chain and Sterility Assurance in FY 2011

Another Busy Year of Drug Recalls Led to Shortages of Injectables

Another Busy Year of Drug Recalls Led to Shortages of Injectables

The Return of Part 11

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

Register

Ask The Analyst

Email Article

Sign In To Set a Search Alert

CEOs and Contract Manufacturers Targeted in Latest Warning Letters